Antengene Corporation Limited

DB:722 Stock Report

Market Cap: €54.6m

Antengene Valuation

Is 722 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 722 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 722's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 722's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 722?

Key metric: As 722 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 722. This is calculated by dividing 722's market cap by their current revenue.
What is 722's PS Ratio?
PS Ratio7.5x
SalesCN¥56.07m
Market CapCN¥419.05m

Price to Sales Ratio vs Peers

How does 722's PS Ratio compare to its peers?

The above table shows the PS ratio for 722 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average12.2x
0RX Redx Pharma
13.3x-37.6%€65.0m
HIGH Cantourage Group
29.9x36.7%€58.6m
2FJ0 Pierrel
3.4xn/a€92.8m
APPH Apontis Pharma
2.1x17.3%€84.1m
722 Antengene
7.5x66.1%€448.4m

Price-To-Sales vs Peers: 722 is good value based on its Price-To-Sales Ratio (7.5x) compared to the peer average (12.2x).


Price to Sales Ratio vs Industry

How does 722's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

24 CompaniesPrice / SalesEstimated GrowthMarket Cap
722 7.5xIndustry Avg. 2.9xNo. of Companies32PS0612182430+
24 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 722 is expensive based on its Price-To-Sales Ratio (7.5x) compared to the European Pharmaceuticals industry average (2.9x).


Price to Sales Ratio vs Fair Ratio

What is 722's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

722 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.5x
Fair PS Ratio20.1x

Price-To-Sales vs Fair Ratio: 722 is good value based on its Price-To-Sales Ratio (7.5x) compared to the estimated Fair Price-To-Sales Ratio (20.1x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 722 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.051
€0.20
+289.1%
5.3%€0.21€0.19n/a2
Dec ’25€0.051
€0.20
+281.6%
5.3%€0.21€0.19n/a2
Nov ’25€0.07
€0.20
+180.7%
5.3%€0.21€0.19n/a2
Oct ’25€0.06
€0.20
+227.5%
5.3%€0.21€0.19n/a2
Sep ’25€0.044
€0.19
+340.9%
4.3%€0.20€0.19n/a2
Aug ’25€0.035
€0.21
+504.2%
11.9%€0.24€0.19n/a2
Jul ’25€0.063
€0.21
+238.5%
11.5%€0.24€0.19n/a2
Jun ’25€0.093
€0.21
+128.1%
11.5%€0.24€0.19n/a2
May ’25€0.095
€0.21
+124.5%
11.5%€0.24€0.19n/a2
Apr ’25€0.096
€0.21
+122.1%
11.5%€0.24€0.19n/a2
Mar ’25€0.12
€0.50
+315.4%
48.0%€0.74€0.26n/a2
Feb ’25€0.13
€0.50
+292.5%
48.0%€0.74€0.26n/a2
Jan ’25€0.21
€0.51
+149.9%
43.7%€0.74€0.29n/a2
Dec ’24€0.23
€0.51
+127.8%
43.7%€0.74€0.29€0.0512
Nov ’24€0.16
€0.54
+231.2%
34.6%€0.74€0.29€0.073
Oct ’24€0.13
€0.54
+331.1%
34.6%€0.74€0.29€0.063
Sep ’24€0.12
€0.66
+434.9%
8.2%€0.73€0.60€0.0443
Aug ’24€0.15
€0.74
+383.7%
18.6%€0.93€0.60€0.0353
Jul ’24€0.16
€0.80
+401.1%
17.7%€0.96€0.63€0.0634
Jun ’24€0.20
€0.80
+300.9%
17.7%€0.96€0.63€0.0934
May ’24€0.28
€0.80
+190.5%
17.7%€0.96€0.63€0.0954
Apr ’24€0.30
€0.87
+190.8%
13.4%€0.97€0.71€0.0963
Mar ’24€0.46
€1.19
+155.4%
38.2%€1.81€0.76€0.123
Feb ’24€0.62
€1.20
+93.7%
40.1%€1.87€0.75€0.133
Jan ’24€0.60
€1.20
+100.2%
40.1%€1.87€0.75€0.213
Dec ’23€0.47
€1.30
+176.8%
42.6%€1.85€0.75€0.232

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies